Press

Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023

Feb 24 • 1 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT. The discussion will focus on Numinus’ CRO activities…

FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302

Feb 23 • 5 min read

FSD Pharma Inc. (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced upcoming participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum being held Feb….

Cybin Announces Streamlined Clinical Alignment

Feb 23 • 4 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced a streamlining plan aimed at maximizing the Company’s operating efficiency and to allow the Company to focus on critical clinical trials. Based on anticipated cost savings from the streamlining exercise and the Company’s ongoing and previously announced US$35 million At-The-Market…

PSLY.com, Inc. Ei.Ventures, Inc. and Mycotopia Therapies Inc. Terminate Agreement and Plan of Merger

Feb 23 • 2 min read

Ei.Ventures, Inc. and Mycotopia Therapies Inc. (OTC: TPIA) announced today that on February 16, 2023, PSLY.com, Inc., Ei.Ventures and Mycotopia Therapies agreed to mutually terminate the Agreement and Plan of Merger, dated May 17, 2022, which provided for the acquisition of Ei.Ventures and Mycotopia Therapies by PSLY.com, Inc. by way of triangular merger, wherein the two companies would…

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Feb 23 • 3 min read

PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs). The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021. This PCT application disclosed novel compositions of MDMA and analogs thereof, which may…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435